Holen Sie sich die Stockscreener-App
0.0507
41.76%
-0.0364
Bio Path Holdings Inc Aktie (BPTH) Neueste Nachrichten
Standex International Corporation 2026 Q1 Financial Results and SEC Filing Overview - Minichart
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path - Barchart.com
TELA Bio Announces Strategic Board Refreshment with Four Highly Experienced Commerical Leaders to Accelerate Growth and Drive Path to Profitability; The Company Also Reports Preliminary First Quarter 2026 Revenues - Yahoo Finance
[1-K] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Leading Companies Consolidating Their Presence in the Antisense and RNAi Therapeutics Market - openPR.com
MSN Money - MSN
RNA Therapies Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Expands as 50+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Grows as 70+ Pharma Companies Advance Novel Treatments for Genetic and Rare Diseases, Finds DelveInsight | Novartis, Wave Life Sciences, Bio-Path Holdin - Barchart.com
Layoff Tracker: Replimune lays off over 200 in Massachusetts - BioSpace
5E Advanced Materials, Inc. Files Form 8-K with Nasdaq Listing Details and Emerging Growth Company Status - Minichart
In-Depth Examination of Segments, Industry Trends, and Key - openPR.com
Microbot Medical Inc. (MBOT) stock price, news, quote and history - Yahoo Finance Australia
Stock List: Research Stocks from Around the World - GuruFocus
USA Stocks: Research Stocks from USA Stock Market - GuruFocus
Analyzing Bio-Path (BPTH) and Its Rivals - defenseworld.net
IXICO Taps Tech Bio Path with Strategic Medidata Deal - kalkinemedia.com
Bio-Path Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
[1-A] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Shows Potential with Active Contributions from 70+ Key Companies | DelveInsight - Barchart.com
Bio-Path Holdings, Inc. Announces Domestication to Wyoming and Amendment Creating Series S Preferred Stock - Minichart
Bio-Path Holdings approves Wyoming move and creates new preferred stock class - Investing.com Australia
[8-K] BIO-PATH HOLDINGS, INC. Reports Material Event - Stock Titan
Reviewing Bio-Path (NASDAQ:BPTH) & Turn Therapeutics (NASDAQ:TTRX) - Defense World
SEC Filings for Mar 19, 202610-K, 10-Q, 8-K Forms - Stock Titan
Gossamer Bio 2025 Annual Report: Seralutinib PAH Clinical Development, FDA Path, and Regulatory Strategy Insights - Minichart
Vuzix Reports 2025 Financial Results, Secures $20M Quanta Investment, and Advances Waveguide & OEM Smart Glasses Growth - Minichart
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - Barchart.com
T-Cell Malignancies Clinical Trial Pipeline Accelerates as 75+ - openPR.com
Is Bio Path Holdings Inc. (IBP0) stock a defensive play amid uncertaintyQuarterly Trade Review & Long Hold Capital Preservation Plans - Naître et grandir
[1-Z] BIO-PATH HOLDINGS, INC. SEC Filing - Stock Titan
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split By Investing.com - Investing.com South Africa
Bio-Path Holdings issues preferred shares, plans Wyoming move, cancels reverse split - Investing.com Australia
Bio-Path (BPTH) grants CEO affiliate new preferred shares and weighs trial restarts - Stock Titan
BPTHBio-Path Hldgs Inc Latest Stock News & Market Updates - Stock Titan
Head-To-Head Comparison: eFFECTOR Therapeutics (NASDAQ:EFTR) & Bio-Path (NASDAQ:BPTH) - Defense World
Can Bio Path Holdings Inc. (IBP0) stock surprise markets with earningsRate Cut & AI Optimized Trade Strategies - mfd.ru
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease - Yahoo Finance
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Marginal Zone Lymphoma Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working In The Domain Delveinsight - Mena FN
Acute Myeloid Leukemia Market Forecast to 2034: 7MM Opportunity, Strong CAGR, 43,500 Annual Cases, and Pipeline-Driven Growth | DelveInsight - Barchart.com
Acute Myeloid Leukemia Market Forecast to 2034: 7MM - openPR.com
ImmunityBio Advances Regulatory Discussions with FDA on Potential Resubmission Path for ANKTIVA® in BCG-Unresponsive Papillary Bladder Cancer - Yahoo Finance
Antisense Oligonucleotide Therapeutics Clinical Trial - openPR.com
Antisense Oligonucleotide Therapeutics Clinical Trial Pipeline Appears Robust With 70+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Barchart.com
Bio-Path Holdings Q3 2025: Loss of $976K, Shares at $0.07News and Statistics - IndexBox
Bio-Path: Third Quarter Financial Highlights - Bitget
Bio-Path: Q3 Earnings Snapshot - Barchart.com
BPTH: Operational pause, depleted cash, and debt defaults highlight urgent need for new funding - TradingView
BIO-PATH HOLDINGS, INC. SEC 10-Q Report - TradingView
1.25%
3.16%
Kapitalisierung:
|
Volumen (24h):